Robert Gerety

Gerety, Robert 4148350_19817162 TP.jpg

Title: Microbiologist, Researcher, Pediatrician, Pharmaceutical Executive, Drug Developer
Location: Natick, Massachusetts, United States

Robert Gerety, Microbiologist, Researcher, Pediatrician, Pharmaceutical Executive and Drug Developer, has been recognized by Marquis Who’s Who Top Scientists and Top Doctors for dedication, achievements, and leadership in microbiology, pharmaceutical research and science.

Dr. Gerety can still remember the excitement he felt the first time he looked through the eyepiece of a microscope. It is the impetus of what inspired him to pursue his profession in the science and medical fields. He first pursued science, earning a Bachelor of Arts with special honors from Rutgers University in 1962, and following this degree with a Master of Arts and PhD at Stanford University in 1966 and 1971, respectively. While matriculating, he realized he could make a big difference in people’s lives by also earning an MD, and in 1970, he received a medical degree from George Washington University. In this capacity, he has been able to help develop drugs and treat patients from several standpoints. Prior to retiring, he served as the Chief Development Officer of Medicine in Need. Dr. Gerety previously worked at Nektar Therapeutics, Inhale Therapeutic Systems, Cell Gate Inc., ORAVAX, Immulogic Pharmaceutical Corp., Merck Research Laboratories, the Food and Drug Administration, the National Institutes of Health, Stanford University Hospital and a variety of other well-regarded institutions.

In his career, Dr. Gerety has had a number of achievements. These include major contributions to the development and/or approval of a vaccine against Hepatitis A and Hepatitis B, pediatric vaccines including Hemophilus Influenza B and varicella, Biogen’s beta interferon product to treat multiple sclerosis (Avonex) Medicines Company’s product (Angiomax) a direct thrombin inhibitor; patents for Inactivation of Non-A, Non-B Hepatitis Agent; Hepatitis B Immune Globulin used to Inactivate Hepatitis B Virus in Injectable Biological Products; Detection of Non-A, Non-B Hepatitis Associated Antigen; Heat Treatment of a Non-A, Non-B Hepatitis Agent to Prepare a Vaccine; Hepatitis B Core Antigen Vaccine; Hepatitis B Core Antigen Vaccine Made by Recombinant DNA; Purified Antigen from Non-A, Non-B Hepatitis Causing Factor: Screening Test for Reverse Transcriptase Containing Viruses in human blood. For his work, he has received a Commendation Medal from the US Public Health Service, an Outstanding Service Medal, a Distinguished Service Medal and a Patriotic Service Award. He has also been recognized as a Henry Rutgers Fellow and a fellow of the National Institutes of Health.

Contact Dr. Gerety:

Leave a Reply